Australia has recently introduced a new childhood vaccine called VAXELIS into the National Immunisation Program (NIP), as an alternative to Infanrix Hexa. This vaccine is administered to infants at 2, 4, and 6 months to protect against DTPa, hepB, p…
Australia has recently introduced a new childhood vaccine called VAXELIS into the National Immunisation Program (NIP), as an alternative to Infanrix Hexa. This vaccine is administered to infants at 2, 4, and 6 months to protect against DTPa, hepB, polio, and HIB.
It's concerning that healthcare professionals have not been provided with any details about Vaxelis beyond its interchangeability with Infanrix Hexa. The official Product Information for Vaxelis states that it's a ribosomal DNA vaccine.
The decision to include a genetic vaccine in the NIP without sufficient transparency is raising serious questions and concerns. Parents are cautioned to exercise caution and seek more information before allowing this vaccine for their child.
The lack of information on clinical trials, safety data, and the absence of a clear explanation for these changes is indeed worrisome. Previously, immunizers had to complete educational requirements before administering vaccines. However, recent NIP schedule changes have been poorly communicated, which is unusual given the meticulous approach to schedule modifications in the past.
The inclusion of a new genetic vaccine without the necessary information and transparency is a matter of concern. It's essential for healthcare authorities to provide detailed information and ensure the safety of vaccines before introducing them into the immunization program.
#Vaxelis #ChildhoodVaccine #NationalImmunisationProgram #HealthcareTransparency #ParentalConcerns #VaccineSafety #MedicalTransparency #NIPChanges #HealthcareEducation #PublicHealthAlert #VaccineInformation #GeneticVaccine #ClinicalTrials #HealthcareAdvocacy #VaccineConcerns #TrinidadandTobagoWarning
